TBnet webinar
Today, 31 October at 17:00 CET the TBnet webinar "Role of surgery in TB”.
More information and free registration:
TBnet at the UNION Conference
If you are at the UNION World Conference on Lung Diseases, don’t miss the presentation of the results of the joint TBnet/ESMYG study.
Thursday, November 14, 16:10 – 17:40
LB03 The RIT/JATA student late-breaker session
LB03-1219-14 Extensively-drug-resistant TB: Back to the pre-antibiotic era? A TBnet/ESGMYC multi-country study
Oral Presenter: Ole Skouvig Pedersen (Aarhus, Denmark)
Other interesting presentations:
Wednesday, November 13, 11:00 - 12:10
Plenary session
PL-01 Access to medicines and diagnostics
Wednesday, November 13, 16:10 – 17:40
Late breaker session
LB02-1213-13 endTB-Q: Interim results of a randomised controlled trial testing a shorter treatment strategy for pre-XDR TB
Oral Presenter: Lorenzo Guglielmetti (Paris, France)
Wednesday, November 13, 14:20 – 15:50
OA07 Identifying and managing TB infection
OA07-154-13 Safety profile of levofloxacin preventive treatment for multi-drug-resistant TB: A meta-analysis of the VQUIN and TB-CHAMP trials
Oral Presenter: Trinh Duong (London, United Kingdom)
Saturday, November 16, 09:30 – 11:00
OA49 Filling in the TB knowledge gaps: Research in action from new drugs to operational research
OA49-491-16 Fourteen-day treatment responses in participants with rifampicin-susceptible pulmonary TB receiving ganfeborole in combination with delamanid or bedaquiline: A phase 2a open-label, randomised trial
Oral Presenter: Simon Tiberi (London, United Kingdom)
Saturday, November 16, 09:10 – 09:55
TBScience session
TBS4B Pharmacological considerations for optimising new regimens
TBS4B-25 A 4-month regimen of quabodepistat, delamanid, and bedaquiline for drug-susceptible pulmonary TB
Oral Presenter: Mohammed Rassool (Johannesburg, South Africa)
Essential TB read
The World Health Organization released the Global Tuberculosis Report 2024.
Tuberculosis is again the world’s leading infectious disease killer, surpassing COVID-19. A global total of 8.2 million people were reported as newly diagnosed with TB in 2023, up from 7.5 million in 2022 and 7.1 million in 2019.
The global gap between the estimated number of people developing TB (incident cases) and the reported number of people newly diagnosed with TB (notified cases) narrowed to a best estimate of 2.7 million in 2023, down from about 4 million in both 2020 and 2021 and below the pre-pandemic level of 3.2 million in 2019.
The treatment success rate for drug-susceptible TB remains high (at 88%) and has improved to 68% for MDR/RR-TB.
TB research remains severely underfunded with only US$1 billion invested in 2022, out of target US$5 billion annually.
TBnet News
Editor – Irina Kontsevaya
Layout & formatting – Liga Rusmane
Cover picture – Maria Victoria Veras
Comments